Nektar Therapeutics (NKTR) — Stock Price, Chart & Analysis
Nektar Therapeutics (NKTR) is a Healthcare stock currently trading at $60.97, down 7.20% on the day. It carries a market capitalization of $2.08B. Over the past 52 weeks, NKTR has traded between $33.40 and $109.00. Nektar Therapeutics does not currently pay a regular dividend. View the live NKTR chart, technical opinion, analyst ratings, fundamentals and latest news below.
Nektar Therapeutics (NKTR) key data
| Price | $60.97 |
| Change (today) | -7.20% |
| Previous close | $65.7 |
| Market cap | $2.08B |
| EPS (TTM) | $-6.12 |
| 52-week high | $109.00 |
| 52-week low | $33.40 |
| Beta | 1.15 |
| Avg. volume | 892.6K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Nektar Therapeutics (NKTR)
How much does one share of Nektar Therapeutics cost?
As of the latest update, one share of Nektar Therapeutics (NKTR) trades at $60.97 (-7.20% today).
What is Nektar Therapeutics's market cap?
Nektar Therapeutics has a market capitalization of approximately $2.08B.
What is Nektar Therapeutics's earnings per share (EPS)?
Nektar Therapeutics's trailing twelve-month EPS is $-6.12.
Does Nektar Therapeutics pay a dividend?
Nektar Therapeutics does not currently pay a regular dividend.
What is Nektar Therapeutics's 52-week trading range?
Over the past year, NKTR has traded between $33.40 and $109.00.
What is the analyst price target for Nektar Therapeutics?
The mean analyst price target for Nektar Therapeutics is $144.40. This is informational only and not investment advice.
Latest Nektar Therapeutics (NKTR) news
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)News · Aug 28, 2026
- Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year TestNews · Aug 27, 2026
- Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisNews · Aug 25, 2026
- Nektar (NKTR) Q2 2026 Earnings Call TranscriptNews · Aug 20, 2026
- Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings SurpriseNews · Aug 15, 2026
- Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial LaunchNews · Aug 14, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live NKTR dashboard…